Literature DB >> 10823824

The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface.

D H Ho1, K Badellino, F A Baglia, M F Sun, M M Zhao, D Gailani, P N Walsh.   

Abstract

We have reported that prothrombin (1 microm) is able to replace high molecular weight kininogen (45 nm) as a cofactor for the specific binding of factor XI to the platelet (Baglia, F. A., and Walsh, P. N. (1998) Biochemistry 37, 2271-2281). We have also determined that prothrombin fragment 2 binds to the Apple 1 domain of factor XI at or near the site where high molecular weight kininogen binds. A region of 31 amino acids derived from high molecular weight kininogen (HK31-mer) can also bind to factor XI (Tait, J. F., and Fujikawa, K. (1987) J. Biol. Chem. 262, 11651-11656). We therefore investigated the role of prothrombin fragment 2 and HK31-mer as cofactors in the binding of factor XI to activated platelets. Our experiments demonstrated that prothrombin fragment 2 (1 microm) or the HK31-mer (8 microm) are able to replace high molecular weight kininogen (45 nm) or prothrombin (1 microm) as cofactors for the binding of factor XI to the platelet. To localize the platelet binding site on factor XI, we used mutant full-length recombinant factor XI molecules in which the platelet binding site in the Apple 3 domain was altered by alanine scanning mutagenesis. The recombinant factor XI with alanine substitutions at positions Ser(248), Arg(250), Lys(255), Leu(257), Phe(260), or Gln(263) were defective in their ability to bind to activated platelets. Thus, the interaction of factor XI with platelets is mediated by the amino acid residues Ser(248), Arg(250), Lys(255), Leu(257), Phe(260), and Gln(263) within the Apple 3 domain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823824     DOI: 10.1074/jbc.M001890200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Microneme proteins in apicomplexans.

Authors:  Vern B Carruthers; Fiona M Tomley
Journal:  Subcell Biochem       Date:  2008

Review 2.  Structure and function of factor XI.

Authors:  Jonas Emsley; Paul A McEwan; David Gailani
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

3.  Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2).

Authors:  Tara C White-Adams; Michelle A Berny; Erik I Tucker; Jacqueline M Gertz; David Gailani; Rolf T Urbanus; Philip G de Groot; András Gruber; Owen J T McCarty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

Review 4.  The many faces of the contact pathway and their role in thrombosis.

Authors:  Rebecca S Woodruff; Bruce Sullenger; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

5.  A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets.

Authors:  Tara N Miller; Dipali Sinha; T Regan Baird; Peter N Walsh
Journal:  Biochemistry       Date:  2007-11-17       Impact factor: 3.162

6.  Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation.

Authors:  Stephen B Smith; Ingrid M Verhamme; Mao-fu Sun; Paul E Bock; David Gailani
Journal:  J Biol Chem       Date:  2008-01-11       Impact factor: 5.157

Review 7.  Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system.

Authors:  Alvin H Schmaier
Journal:  Int Immunopharmacol       Date:  2007-09-05       Impact factor: 4.932

8.  The dimeric structure of factor XI and zymogen activation.

Authors:  Yipeng Geng; Ingrid M Verhamme; Stephen B Smith; Mao-Fu Sun; Anton Matafonov; Qiufang Cheng; Stephanie A Smith; James H Morrissey; David Gailani
Journal:  Blood       Date:  2013-03-20       Impact factor: 22.113

Review 9.  Interplay between platelets and coagulation.

Authors:  Yaqiu Sang; Mark Roest; Bas de Laat; Philip G de Groot; Dana Huskens
Journal:  Blood Rev       Date:  2020-07-12       Impact factor: 10.626

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.